After the provisions in the whistle blower act, pharma has seen many illegal marketing tactics coming out in public, Pfizer has been targeted many a times and it’s still with its competitor Novartis considered the best in the field of Pharma Marketing
We now need to watch how Pfizer is promoting Tofacitinib and Eliquis?
Last month what astonished me that Amgen was ready to pay back around 750 M USD to federal government as it already knew that it had to pay the price for use of illegal marketing tactics for Arnasep. This is not the first case, for the past 20 years we have seen a tremendous increase in these types of marketing tactics by Pharma and biopharma companies to allure physicians and primary health bodies. As Amgen had already kept aside 750 M USD from its revenue. Going forward we will observe that companies as part of their marketing budget will keep additional 1B USD in cash for these type of situations.
As whistleblower act has been promoted in US we have more to watch!
We now need to watch how Pfizer is promoting Tofacitinib and Eliquis?
Last month what astonished me that Amgen was ready to pay back around 750 M USD to federal government as it already knew that it had to pay the price for use of illegal marketing tactics for Arnasep. This is not the first case, for the past 20 years we have seen a tremendous increase in these types of marketing tactics by Pharma and biopharma companies to allure physicians and primary health bodies. As Amgen had already kept aside 750 M USD from its revenue. Going forward we will observe that companies as part of their marketing budget will keep additional 1B USD in cash for these type of situations.
As whistleblower act has been promoted in US we have more to watch!
No comments:
Post a Comment